Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: effects on myocardial salvage

Int J Cardiol. 2013 Oct 9;168(4):3954-62. doi: 10.1016/j.ijcard.2013.06.053. Epub 2013 Jul 19.

Abstract

Background: We examined the effects of peri-procedural intensive glycemic control during early percutaneous coronary intervention (PCI) on the number and differentiation of endothelial progenitor cells (EPCs) and myocardial salvage (MS) in hyperglycemic patients with first ST-elevation myocardial infarction (STEMI).

Methods and results: We conducted a randomized, prospective, open label study on 194 patients with STEMI undergoing PCI: 88 normoglycemic patients (glucose < 140 mg/dl) served as the control group. Hyperglycemic patients (glucose ≥140 mg/dl) were randomized to intensive glycemic control (IGC) for almost 24 h after PCI (n = 54; 80-140 mg/dl) or conventional glycemic control (CGC, n = 52; 180-200 mg/dl). EPC number, differentiation, and SIRT1expression were assessed immediately before, 24 h, 7, 30 and 180 days after PCI. The primary end point of the study was salvage index, measured as the proportion of initial perfusion defect (acute technetium-99m sestamibi scintigraphy, performed 5 to 7 days after STEMI) and myocardium salvaged by therapy (6 months after STEMI). Hyperglycemic patients had lower EPC number and differentiation and lower SIRT1 levels than normoglycemic patients (P < 0.01). After the insulin infusion, mean plasma glucose during peri-procedural period was greater in CGC group than in IGC group (P < 0.001). The EPC number, their capability to differentiate, and SIRT1 levels were significantly higher in IGC group than in CGC, peaking after 24 h (P < 0.01). In the IGC group, the salvage index was greater than in patients treated with CGC (P < 0.001).

Conclusions: Optimal peri-procedural glycemic control, by increasing EPC number and their capability to differentiate, may improve the myocardial salvage.

Trial registration: ClinicalTrials.gov NCT01016509.

Keywords: AMI; CGC; EPCs; Endothelial progenitor cells; IGC; MS; Myocardial infarction; PBMC; PCI; SIRT1; ST-segment elevation myocardial infarction; STEMI; acute myocardial infarction; conventional glycemic control; endothelial progenitor cells; intensive glycemic control; myocardial salvage; percutaneous coronary intervention; peripheral blood mononuclear cells; silent information regulator 1.

Publication types

  • Observational Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Blood Glucose / metabolism*
  • Cell Differentiation / physiology*
  • Cells, Cultured
  • Endothelial Cells / metabolism
  • Female
  • Follow-Up Studies
  • Glycemic Index / physiology
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / blood*
  • Myocardial Infarction / surgery*
  • Myocardium / metabolism
  • Myocardium / pathology
  • Percutaneous Coronary Intervention / adverse effects
  • Percutaneous Coronary Intervention / methods*
  • Preoperative Care / methods
  • Prospective Studies
  • Salvage Therapy / methods
  • Stem Cells / metabolism*
  • Time Factors
  • Treatment Outcome

Substances

  • Blood Glucose

Associated data

  • ClinicalTrials.gov/NCT01016509